Vinpocetine inhibits breast cancer cells growth in vitro and in vivo

Apoptosis

Volumn 17, Issue 10, 2012, Pages 1120-1130

  Huang, Er Wen ^a   Xue, Sheng Jiang ^a,b   Zhang, Zheng ^a   Zhou, Jia Guo ^a   Guan, Yong Yuan ^a   Tang, Yong Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Apoptosis; Breast cancer; Proliferation; STAT3; Vinpocetine

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MIGRATION INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; VINCA ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84868114145     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-012-0743-0     Document Type: Article

References (51)

1. Liu L, Zhang J, Wu AH, Pike MC, Deapen D (2012) Invasive breast cancer incidence trends by detailed race/ethnicity and age. Int J Cancer 130:395-404
2. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61:409-418
3. Smigal C, Jemal A, Ward E et al (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183 (Pubitemid 43847927)
4. Rochefort H (1987) Nonsteroidal antiestrogens are estrogenreceptor- targeted growth inhibitors that can act in the absence of estrogens. Horm Res 28:196-201
5. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51:227-238 (Pubitemid 29054556)
6. Stacey SN, Sulem P, Jonasdottir A et al (2011) A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 43:1098-1103
7. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132:363-374 (Pubitemid 351191995)
8. Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215
9. Garcia R, Bowman TL, Niu G et al (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513 (Pubitemid 32531347)
10. Szilagyi G, Nagy Z, Balkay L et al (2005) Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 229-230:275-284 (Pubitemid 40341594)
11. Dezsi L, Kis-Varga I, Nagy J, Komlodi Z, Karpati E (2002) Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke. Acta Pharm Hung 72:84-91
12. Bagoly E, Feher G, Szapary L (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv Hetil 148:1353-1358 (Pubitemid 47490190)
13. Hagiwara M, Endo T, Hidaka H (1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33:453-457 (Pubitemid 14163168)
14. Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U (1996) Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 24:129-134 (Pubitemid 26226248)
15. Sitges M, Galvan E, Nekrassov V (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 46:533-540 (Pubitemid 40544400)
16. Bonoczk P, Gulyas B, Adam-Vizi V et al (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 53:245-254
17. Jeon KI, Xu X, Aizawa T et al (2010) Vinpocetine inhibits NFkappaB- dependent inflammation via an IKK-dependent but PDEindependent mechanism. Proc Natl Acad Sci USA 107:9795-9800
18. 2+/ calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98:777-784
19. Tang YB, Liu YJ, Zhou JG, Wang GL, Qiu QY, Guan YY (2008) Silence of ClC-3 chloride channel inhibits cell proliferation and the cell cycle via G/S phase arrest in rat basilar arterial smooth muscle cells. Cell Prolif 41:775-785
20. Li SY, Wang XG, Ma MM et al (2012) Ginsenoside-Rd potentiates apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells through the mitochondrial pathway. Apoptosis 17:113-120
21. Shi XL, Wang GL, Zhang Z et al (2007) Alteration of volumeregulated chloride movement in rat cerebrovascular smooth muscle cells during hypertension. Hypertension 49:1371-1377 (Pubitemid 46809382)
22. Terradillos O, Montessuit S, Huang DC, Martinou JC (2002) Direct addition of BimL to mitochondria does not lead to cytochrome c release. FEBS Lett 522:29-34 (Pubitemid 34722493)
23. Wang GL, Wang XR, Lin MJ, He H, Lan XJ, Guan YY (2002) Deficiency in ClC-3 chloride channels prevents rat aortic smooth muscle cell proliferation. Circ Res 91:E28-E32
24. Dimco G, Knight RA, Latchman DS, Stephanou A (2010) STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. Cell Cycle 9:4638-4649
25. Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882-10894
26. Nakayama K, Ishida N, Shirane M et al (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720
27. Fuchs Y, Steller H (2011) Programmed cell death in animal development and disease. Cell 147:742-758
28. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM (2009) Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69:1958-1965
29. Badache A, Hynes NE (2001) Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61:383-391 (Pubitemid 32095742)
30. Constantinescu SN, Girardot M, Pecquet C (2008) Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 33:122-131
31. Garcia R, Yu CL, Hudnall A et al (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8:1267-1276 (Pubitemid 28008723)
32. Song L, Turkson J, Karras JG, Jove R, Haura EB (2003) Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22:4150-4165 (Pubitemid 36876236)
33. Ferrajoli A, Faderl S, Ravandi F, Estrov Z (2006) The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6:671-679 (Pubitemid 44875961)
34. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945-954 (Pubitemid 35177340)
35. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8:409-422 (Pubitemid 39359648)
36. Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, Lee JM (2007) eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 26:3027-3040 (Pubitemid 46733638)
37. Li Z, Qi CF, Shin DM et al (2010) Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One 5:e10755
38. Ahn HS, Crim W, Pitts B, Sybertz EJ (1992) Calcium-calmodulinstimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprot Res 25:271-288
39. 2+ channels: effects of bifemelane and several nootropic agents. Eur J Pharmacol 189:51-58 (Pubitemid 20252996)
40. Erdo SA, Molnar P, Lakics V, Bence JZ, Tomoskozi Z (1996) Vincamine and vincanol are potent blockers of voltage-gated Na?channels. Eur J Pharmacol 314:69-73 (Pubitemid 26378887)
41. Dunkern TR, Hatzelmann A (2007) Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 274:4812-4824 (Pubitemid 47353125)
42. Savai R, Pullamsetti SS, Banat GA et al (2010) Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs 19:117-131
43. Sengupta R, Sun T, Warrington NM, Rubin JB (2011) Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 32: 337-344
44. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancerrelated inflammation. Nature 454:436-444
45. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423 (Pubitemid 40719125)
46. Rebouissou S, Amessou M, Couchy G et al (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457:200-204
47. Huber MA, Azoitei N, Baumann B et al (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569-581 (Pubitemid 39572107)
48. Luo JL, Tan W, Ricono JM et al (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690-694 (Pubitemid 46606879)
49. Mantovani A (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10:369-373
50. Medina AE (2010) Vinpocetine as a potent antiinflammatory agent. Proc Natl Acad Sci USA 107:9921-9922
51. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436 (Pubitemid 44050137)